

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should also be reported to McNeil Products Limited on 01344 864 042.

Regaine For Men Extra Strength Scalp Foam 5% w/w Cutaneous Foam (Minoxidil) Product Information

Presentation:

Cutaneous foam containing Minoxidil 50mg/g (5% w/w).

Uses:

Treatment of alopecia androgenetica in men aged 18 to 49.

Dosage:

1g twice daily to affected areas of scalp. Maximum dose 2g in 24 hours.

Contraindications:

Hypersensitivity to ingredients. Hypertension, scalp abnormality, shaved scalp, occlusive dressings on scalp or other topical medications. Also contraindicated for use in women.

Precautions:

For external use only on normal healthy scalp. Wash hands thoroughly after application. Avoid contact with eyes or sensitive surfaces. Stop use and see doctor if hypotension or other cardiovascular symptoms of systemic absorption develops. Patients with cardiovascular disease or arrhythmia to contact physician before use. Foam contains ethanol (alcohol), which will cause burning and irritation of the eye. Foam also contains butylated hydroxytoluene, cetyl and stearyl alcohol which may cause local skin reactions. This product may cause dizziness or hypotension. If affected, patients should not drive or operate machinery.

Pregnancy and Lactation:

Should not be used.

Side effects:

Very common: headache.

Common: hypersensitivity reactions, chest pain, hypertrichosis, pruritus, rash, dermatitis, oedema peripheral and weight increase.

Uncommon: Dizziness, palpitation, dyspnea, and nausea

Not known: Angiodema, depressed mood, eye irritation, heart rate increased, hypotension, vomiting, dry skin, acne (acneiform rash), temporary hair loss, changes in hair colour and application site reactions.

Rare: changes in hair texture

RRP (ex VAT): Single pack- £31.11; Triple pack- £66.69.

Legal category: GSL.

PL Holder: McNeil Products Ltd, Foundation Park, Maidenhead, Berks, SL6 3UG

PL Number(s): 15513/0366.

Date of prep: 01 May 2018

UK/RE/15-5999(5)